KTOV (Market Cap $20 M ) (Cash $11 M) FDA Decision
Post# of 35
(Total Views: 540)
Posted On: 10/09/2017 10:16:36 AM
KTOV (Market Cap $20 M ) (Cash $11 M) FDA Decision in Q2 + Phase 3 Results this Q / Shares Out: 10.6 M = HUGE Upside Potential here
Kitov Phama (KTOV)
Market Cap $20 Miillion
Cash $11 Million
Price: 1.94
Shares Out 10.6 Million
Kitov Announces FDA Acceptance of NDA for KIT-302
https://www.baystreet.ca/articles/research_re...100317.pdf
KIT-302 is a Treatment for Hypertension and Osteoarthritis Pain.
KIT-302 is a fixed dose combination drug comprised of the nonsteroidal anti-inflammatory drug (NSAID)celecoxib, and the well-known antihypertensive agent, amlodipine besylate. Celecoxib monotherapy often leads to hypertension, which if uncontrolled, can increase the risk of heart attack and stroke. KIT-302 is designed to provide a solution for physicians who avoid prescribing NSAIDs for osteoarthritis pain due to their hypertensive side effects. There is currently no single drug for the treatment of pain and hypertension, so, if approved, KIT-302 could be a unique product in the multibillion-dollar osteoarthritis market.
Expected Upcoming Milestones
■Q4 2017 – Top-line results from Phase III kidney function trial.
■Q2 2018 – Expected FDA approval decision for KIT-302.
Kitov Phama (KTOV)
Market Cap $20 Miillion
Cash $11 Million
Price: 1.94
Shares Out 10.6 Million
Kitov Announces FDA Acceptance of NDA for KIT-302
https://www.baystreet.ca/articles/research_re...100317.pdf
KIT-302 is a Treatment for Hypertension and Osteoarthritis Pain.
KIT-302 is a fixed dose combination drug comprised of the nonsteroidal anti-inflammatory drug (NSAID)celecoxib, and the well-known antihypertensive agent, amlodipine besylate. Celecoxib monotherapy often leads to hypertension, which if uncontrolled, can increase the risk of heart attack and stroke. KIT-302 is designed to provide a solution for physicians who avoid prescribing NSAIDs for osteoarthritis pain due to their hypertensive side effects. There is currently no single drug for the treatment of pain and hypertension, so, if approved, KIT-302 could be a unique product in the multibillion-dollar osteoarthritis market.
Expected Upcoming Milestones
■Q4 2017 – Top-line results from Phase III kidney function trial.
■Q2 2018 – Expected FDA approval decision for KIT-302.
(0)
(0)